Nivolumab: all 1,111 studies that test it

Page 2 of 12. Open to participants first (176), then studies with results posted, then the rest; newest registration first within each.

• Effect of Nivolumab vs Placebo in Patients With Acute Myocardial Infarction: A Randomized Clinical TrialNot yet recruitingNCT05887830Phase 1/2
• Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric CancerRecruitingNCT05859477Phase 2
• Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingNCT05845450Phase 2
• Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)RecruitingNCT05795244Phase 2
• Cryoablation+Ipilimumab+Nivolumab in MelanomaRecruitingNCT05779423Phase 2
• First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)RecruitingNCT05749900Phase 1/2
• Intraperitoneal Immune Checkpoint Inhibitor for Malignant AscitesEnrolling by invitationNCT05745233Not applicable
• Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)RecruitingNCT05733689Phase 1
• Immunotherapy in Patients With Early dMMR Rectal CancerRecruitingNCT05732389Phase 2
• Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland CarcinomaRecruitingNCT05727410Phase 2
• Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain MetastasesRecruitingNCT05704647Phase 2
• A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingNCT05675410Phase 3
• MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced MelanomaRecruitingNCT05655312Phase 1/2
• Safe Stop Ipilimumab-nivolumab (IPI-NIVO) TrialRecruitingNCT05652673Not applicable
• Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid MesotheliomaRecruitingNCT05647265Phase 2
• Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint InhibitorsRecruitingNCT05629546Phase 1
• Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid SyndromeNot yet recruitingNCT05597800Phase 2
• Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver MetastasesNot yet recruitingNCT05588297Phase 2
• A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsRecruitingNCT05584670Phase 1/2
• Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerRecruitingNCT05501665Phase 1/2
• Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in MelanomaRecruitingNCT05498792Early Phase 1
• Nivolumab-ipilimumab and Chemoradiation for Cervical CancerRecruitingNCT05492123Phase 2
• Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive CarcinomaNot yet recruitingNCT05461235Phase 2
• Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRCRecruitingNCT05310643Phase 2
• Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaRecruitingNCT05272384Phase 1
• CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular CarcinomaRecruitingNCT05257590Phase 2
• PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerRecruitingNCT05234307Phase 1
• Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder CancerRecruitingNCT05203913Phase 2
• Low Dose Nivolumab in Adults Living With HIV on Antiretroviral TherapyRecruitingNCT05187429Phase 1/2
• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingNCT05136196Phase 2
• Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)RecruitingNCT05112549Phase 1
• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerRecruitingNCT05098210Phase 1
• Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic CancerRecruitingNCT05088889Phase 1
• A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesRecruitingNCT05048212Phase 2
• Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint InhibitorsRecruitingNCT05039073Phase 2
• HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced SarcomaRecruitingNCT04995003Phase 1
• Using ctDNA to Determine Therapies for Lung CancerRecruitingNCT04966663Phase 2
• BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and NivolumabRecruitingNCT04933903Phase 2
• Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AMLRecruitingNCT04913922Phase 2
• Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRCRecruitingNCT04912765Phase 2
• Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVRecruitingNCT04902443Phase 1
• An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)RecruitingNCT04876313Phase 2
• Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based TreatmentRecruitingNCT04875611Phase 2
• Radiation Free Chemotherapy for Early Hodgkin LymphomaRecruitingNCT04866654Phase 2
• Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular CarcinomaRecruitingNCT04823403Phase 1
• PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyRecruitingNCT04745949Phase 2
• Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in MelanomaRecruitingNCT04741997Early Phase 1
• Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare SubtypeRecruitingNCT04741438Phase 3
• Intralesional Influenza Vaccine for the Treatment of Stage I-IV MelanomaRecruitingNCT04697576Phase 1
• Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin LymphomaRecruitingNCT04561206Phase 2
• A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingNCT04546399Phase 2
• GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced SarcomaRecruitingNCT04535713Phase 2
• Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingNCT04472767Phase 2
• The IMmunotherapy Pleural 5-ALA PDTRecruitingNCT04400539Phase 2
• Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar CancerRecruitingNCT04380545Phase 1/2
• DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular CarcinomaRecruitingNCT04248569Phase 1
• Nivolumab for Treatment of Squamous Cell Carcinoma of the SkinRecruitingNCT04204837Phase 2
• Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingNCT03866382Phase 2
• A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI StudyRecruitingNCT03844256Phase 1/2
• INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory MalignanciesRecruitingNCT03838042Phase 1/2
• ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsRecruitingNCT03686124Phase 1/2
• Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb PerfusionRecruitingNCT03685890Phase 1/2
• Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT03681561Phase 1/2
• Melanoma Metastasized to the Brain and SteroidsRecruitingNCT03563729Phase 2
• Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With SarcomaRecruitingNCT03465592Phase 1/2
• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
• Combination of TATE and PD-1 Inhibitor in Liver CancerRecruitingNCT03259867Phase 2
• Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasRecruitingNCT03258567Phase 2
• Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma PatientsRecruitingNCT03166397Phase 2
• SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue SarcomaRecruitingNCT03138161Phase 1/2
• Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic AdenocarcinomaRecruitingNCT03080974Phase 2
• A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingNCT03017820Phase 1
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingNCT02813135Phase 1/2
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
• A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsActive, not recruitingNCT06101134Phase 2Results posted
• A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)TerminatedNCT06094296Phase 2Results posted
• Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant CholangiocarcinomaTerminatedNCT05921760Phase 1/2Results posted
• EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian CancerActive, not recruitingNCT05715216Phase 2Results posted
• A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid TumorsCompletedNCT05407675Phase 1/2Results posted
• A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin LymphomaTerminatedNCT05255601Phase 1/2Results posted
• Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous MelanomaTerminatedNCT05200143Phase 2Results posted
• A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate CancerTerminatedNCT05169684Phase 2Results posted
• A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal MesotheliomaCompletedNCT05041062Phase 2Results posted
• A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelanomaTerminatedNCT05002569Phase 3Results posted
• Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHLActive, not recruitingNCT04938232Phase 2Results posted
• A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)CompletedNCT04907539Phase 2Results posted
• RegoNivo vs Standard of Care Chemotherapy in AGOCCompletedNCT04879368Phase 3Results posted
• First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBVCompletedNCT04778904Phase 1/2Results posted
• A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic TumorsCompletedNCT04761198Phase 1/2Results posted
• A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant CancerTerminatedNCT04730349Phase 1/2Results posted
• A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid TumorsCompletedNCT04704154Phase 2Results posted
• CMP-001 in Combination With Nivolumab in Subjects With Advanced MelanomaTerminatedNCT04698187Phase 2Results posted
• Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable MelanomaTerminatedNCT04688658Phase 1/2Results posted
• Trying to Find the Correct Length of Treatment With Immune Checkpoint TherapyActive, not recruitingNCT04637594Phase 3Results posted
• A Study of Rucaparib and Nivolumab in People With LeiomyosarcomaActive, not recruitingNCT04624178Phase 2Results posted
• Nivolumab Plus Relatlimab in Patients With Metastatic Uveal MelanomaCompletedNCT04552223Phase 2Results posted
• Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma PatientsCompletedNCT04526730Phase 2Results posted
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted

← Nivolumab overview